Fisetin Reverses Vascular Aging Through CXCL12, First Direct Evidence
A compound found in a bowl of strawberries has just produced the first causal evidence that it can reverse vascular aging at the molecular level.
Published in Aging Cell in 2026, the Mahoney team’s paper identified precisely how fisetin, a flavonoid present in everyday fruits, walks back a key driver of vascular dysfunction. The target is CXCL12, a signaling molecule secreted by senescent cells, the so-called “zombie cells” that accumulate with age and poison their surroundings. This is not a correlation study or a broad anti-inflammatory signal. It is a step-by-step causal chain.
Zombie Cells and What They Secrete
Senescent cells are cells that have stopped dividing but refuse to die. Rather than going quietly, they release a continuous stream of inflammatory molecules known as SASP, short for Senescence-Associated Secretory Phenotype. Think of SASP as the exhaust fumes of a cell that should have been removed but wasn’t.
SASP factors recruit neighboring cells into senescence, degrade the structural integrity of blood vessel walls, and sustain low-grade chronic inflammation. This environment has been linked to cardiovascular disease, metabolic dysfunction, and neurodegenerative conditions that accelerate with age. The challenge has always been identifying which specific SASP factors are doing the most damage in vascular tissue, where hundreds of molecules are present simultaneously.
CXCL12, the Vascular Aging Signal
The Mahoney team used single-cell RNA sequencing to profile the aortas of aged mice (27 months) versus young mice (6 months). Scanning thousands of individual cells for expression differences, one factor emerged as consistently elevated in aged endothelial cells: CXCL12.
The critical experiment followed. When researchers injected CXCL12 alone into the plasma of young mice, endothelium-dependent dilation (EDD), the vessel’s ability to expand in response to blood flow, declined. Nitric oxide (NO) bioavailability dropped. The signature of vascular aging appeared in young vessels from a single molecular signal.
Running the experiment in reverse: fisetin treatment in aged mice reduced circulating CXCL12, and vascular function recovered. When CXCL12 was then reintroduced into fisetin-treated aged mice, the recovery was erased. The pathway was confirmed in both directions.
How Fisetin Works as a Senolytic
Fisetin belongs to a class of compounds called senolytics, agents that selectively eliminate senescent cells. Senescent cells survive by activating anti-apoptotic pathways (including the PI3K/AKT axis and BCL-2 family proteins) that override the cell death program. Fisetin disrupts these survival signals, making senescent cells vulnerable to the apoptosis they have been evading.
Beyond direct senolytic clearance, this study found fisetin reduced mitochondrial oxidative stress in vascular endothelial cells and suppressed endothelial-to-mesenchymal transition (EndoMT), a process that contributes to arterial stiffening over time. The paper describes CXCL12 as partially mediating fisetin’s effects, which means additional mechanisms are also at work.
What Food Can Actually Deliver
Fisetin is a naturally occurring flavonoid found in strawberries, apples, and persimmons. Strawberries provide roughly 5mg per 100g; apples provide approximately 26mg per 100g. These are meaningful sources in any phytochemical context.
The gap between food and pharmacological dose, however, is substantial. This study used 100mg per kilogram of body weight in aged mice, administered intermittently via oral gavage. For a 60kg adult, that translates to 6,000mg per day. No amount of strawberries bridges that distance.
The ongoing human trial NCT06133634 at the Mayo Clinic is testing 20mg per kilogram, roughly 1,200mg for a 60kg adult, in 40 participants. Commercial supplements typically run 100 to 500mg per day. Whether that range produces detectable effects on CXCL12 or endothelial function in humans is exactly what the trial is designed to answer.
Fisetin, Quercetin, and Dasatinib: Three Senolytic Candidates
The senolytic field has three primary candidates in active investigation.
Quercetin, found in onions and apples, was the first flavonoid to enter human senolytic trials, paired with dasatinib in a 2019 Mayo Clinic pilot. That study showed the combination reduced SASP biomarkers in patients with idiopathic pulmonary fibrosis. It holds the most human data, though nearly all of it comes from small, early-stage pilots.
Dasatinib is a tyrosine kinase inhibitor originally developed to treat chronic myelogenous leukemia. It has the strongest senolytic potency of the three, but it is a prescription drug, not a supplement. Its side effect profile includes immunosuppression, fluid retention, cardiac arrhythmia, and other serious risks that make self-administration by healthy adults a categorically different consideration.
Fisetin ranked first among 10 flavonoids screened for senolytic potency in fibroblast models. Its food-derived origin gives it a lower toxicity profile than dasatinib, and mechanistic studies like this one are arriving steadily. The CXCL12 pathway is the clearest causal mechanism yet published for any dietary senolytic.
The Distance to Human Data
This study is preclinical. The findings come from aged mice and ex vivo human endothelial cells, not from a randomized controlled trial in people. The history of aging research includes many promising mouse results that did not translate to human benefit, and that track record is worth holding in mind.
NCT06133634, currently enrolling 40 participants at the Mayo Clinic, will be one of the first opportunities to evaluate whether the vascular markers seen in this study move in human subjects at clinically meaningful doses. If CXCL12 levels and endothelial function both shift in that trial, the link from mouse to human will become substantive. Until that data exists, the current evidence supports mechanism, not outcome.
Who This Matters To, and Who Should Be Careful
For adults in their 30s through 50s tracking cardiovascular health and longevity research, this study is an important mechanistic step. It explains the biological rationale behind fisetin’s growing profile. It does not mean a daily supplement will produce the same results.
If you take anticoagulants (warfarin, heparin) or antiplatelet agents (aspirin, clopidogrel), fisetin’s platelet-inhibiting properties create a meaningful interaction risk. Bleeding risk increases. This is not a theoretical concern to check off a list.
During pregnancy or when trying to conceive, fisetin’s safety profile is not adequately studied in humans, and preclinical signals in animals warrant caution.
If you already take a multi-ingredient supplement, check the label before adding standalone fisetin. Anti-aging formulas increasingly include it, and stacking without knowing your baseline dose adds an unnecessary variable.
Q. Can eating more strawberries deliver fisetin’s effects?
Strawberries contain roughly 5mg of fisetin per 100g. The mouse study used 100mg per kilogram of body weight, which for a 60kg adult would translate to 6,000mg. Reaching that level through food alone isn’t realistic. Ongoing clinical trials are testing 100 to 500mg per day in supplement form, but whether those doses produce measurable vascular effects in humans is still an open question.
Q. Quercetin is also called a senolytic. How is fisetin different?
Quercetin entered the first human senolytic trials in combination with dasatinib, making it the compound with the longest track record in people, though most data remains at the small-pilot level. Fisetin ranked highest among 10 flavonoids screened for senolytic potency, and its mechanistic picture is building quickly, as this CXCL12 study shows. Dasatinib is a leukemia drug with serious side effects that put it in a different category from food-derived flavonoids for healthy adults.
Q. I take a blood thinner. Is fisetin safe to add?
Fisetin inhibits platelet aggregation, which raises the potential for increased bleeding when combined with anticoagulants like warfarin or antiplatelet drugs like aspirin or clopidogrel. Large-scale human safety data for supplemental fisetin do not yet exist. If you take prescription medication, the right first step is a conversation with your doctor before adding anything.